HDAC9 and female reproductive organ cancer: While preclinical studies have demonstrated the activity of HDAC and proteasome inhibitors in solid tumors [24–26], including our own work in gynecologic cancer cell lines [27], the mechanisms underlying sensitivity vs. resistance to this combination are not well understood.